The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691)

Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers

(2010) Melissa A. Geller et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Loxoribine, a selective Toll-like receptor 7 agonist, induces maturation of human monocyte-derived dendritic cells and stimulates their Th-1- and Th-17-polarizing capability

(2010) Tanja Dzopalic et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

TLR ligands induce synergistic interferon-β and interferon-λ1 gene expression in human monocyte-derived dendritic cells

(2010) Sanna M. Mäkelä et al.   MOLECULAR IMMUNOLOGY

Ido brings down the pressure in systemic inflammation

(2010) Franz Hofmann   NATURE MEDICINE

Nuclear factor κB (NF-κB) activation primes cells to a pro-inflammatory polarized response to a Toll-like receptor 7 (TLR7) agonist

(2009) Jongdae Lee et al.   BIOCHEMICAL JOURNAL

The global burden of hepatitis C

(2009) Daniel Lavanchy   LIVER INTERNATIONAL

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

(2008) R. Dummer et al.   CLINICAL CANCER RESEARCH

A non-synonymous single nucleotide polymorphism in IFNAR1 affects susceptibility to chronic hepatitis B virus infection

(2008) J. Zhou et al.   JOURNAL OF VIRAL HEPATITIS

Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy

(2008) C. H. Chung   ONCOLOGIST